Statement by Mr. Nicolas Sarkozy, President of the Republic, on French research in health, in Paris on June 4, 2010.

France Nicolas Sarkozy · President of France

4 June 2010 · Meeting with heads of R&D of international pharmaceutical research laboratories and LEEM · Paris, France

Context
Sarkozy addressed international pharmaceutical research leaders and French research heads in Paris on June 4, 2010, to review progress and promote health research partnerships.
Main themes
French health research, public-private research cooperation, pharmaceutical industry competitiveness, biomedical research reform, cardiovascular disease and diabetes research, personalized medicine, Alzheimer's disease, regenerative medicine, research investment, national borrowing for future priorities, Alliance of Life and Health Sciences, research governance restructuring
Duration
~15 min
52nd percentile
Words
1,800
52nd percentile
Sentences
117
70th percentile
Readability
44
45th percentile
Grade
10.9
31st percentile
Syntax
2.70
13th percentile
Vocabulary
2.22
54th percentile

Translated from French

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Economic 50%50%
  • Institutional 20%20%
  • Social 15%15%
  • Ceremonial 12%12%
  • Technological 3%3%
  • Geopolitical 1%1%
  • Environmental 0%0%
  • Not in focus 0%

117 sentences in 70 paragraphs

Ladies and Gentlemen Ministers,

Ladies and Gentlemen Presidents of International Research Laboratories,

Ladies and Gentlemen Presidents and General Directors of LEEM,

Mr. President of the Alliance of Life and Health Sciences and of INSERM, dear André SYROTA,

Mr. General Administrator of CEA, dear Bernard Bigot,

Mr. President of CNRS, dear Alain Fuchs,

Professors,

Ladies and Gentlemen,

I am very happy to see you again, one year - to the day - after our last meeting.

I wanted to meet, together, the heads of Research and Development of International Pharmaceutical Research Laboratories, and those of LEEM, which brings together companies in the pharmaceutical sector operating in France.

We had agreed, you will remember, to take stock after a year. You, to tell me what you have done. Me, to tell you where we stand. To convince you that France is changing. And to invite you to look at this France with a new perspective.

Health research is the top priority of our research. The health industries are a major axis of France's competitiveness.

France is the largest producer of medicines in the European Union. The pharmaceutical industry ranks second in the domestic R&D spending of our country.

Last year, we gathered to discuss diseases of the nervous system. This meeting was, I know, a success. Seven partnerships are currently being developed.

An ambitious scientific cooperation agreement between the Alliance of Life and Health Sciences and Sanofi-Aventis has been signed.

Twelve trials have been launched, including an international clinical trial led by ROCHE and directed by Professor Bruno Dubois. Two other contracts, also signed by ROCHE, concern the early diagnosis of Alzheimer's disease.

This year, we have invited you to get to know the best French research teams in the field of cardiovascular diseases, obesity, and diabetes.

French researchers have made major advances in understanding the mechanisms of hypertension, diabetes, and obesity in recent years.

You will also notice that you are not facing the multitude of organizations and agencies that made up the fragmented landscape of French biomedical research just three years ago.

No, it is the Alliance of Life and Health Sciences and its president, André SYROTA, who have organized, with you and for you, today's scientific meeting. The Alliance now brings together all public actors in French biomedical research.

The Alliance is intended to play, like the National Institutes of Health in the United States, a central role in the national steering of research.

I want to remind you once again how much I rely on the Alliance to trust the Universities, to help them in their evolution towards autonomy. In a word, to enable them to fulfill their new missions.

We had to clarify the missions of each. The strategic role is entrusted to the Alliance, the project funding role to ANR, the evaluation role to the Research Evaluation Agency, AERES, and the operational role to the Universities.

And to our researchers, in whom I place so much hope, I would like to say that we need to learn to cooperate better with industrial research.

I took note, during the Strategic Council of Health Industries last October, of the commitment of the main laboratories based in France to double their spending on partnership research by 2012.

In the face of the growing difficulties of therapeutic innovation, we need more than ever a close cooperation between public and industrial research. We have managed to do this for civil nuclear power and aerospace. We will do it for medicine!

We are moving from collective medicine to personalized medicine, capable of predicting the individual effectiveness of treatments. This is already, I believe, the case for treatments for several cancers. And together, with drugs derived from biotechnology and with adult stem cells, you will, I am sure, contribute decisively to the rise of regenerative and reparative medicine.

By encouraging you, once again this year, to cooperate more closely, I renew the wish that a climate of trust be established among you.

There is no question for a second of subordinating research to its only applications. The great discoveries of science are fortuitous, I know that. It is even less a question of subjecting Universities to the laws of the market or of having science driven by the economy.

What is at stake is bouncing back after the most serious crisis that France and the world have known since the 1930s.

It is from investment that technical progress is born, the engine of growth. We must invest to catch up on the delays caused by the crisis, certainly, but also by years of hesitation.

Since 1974, we have constantly sacrificed investment.

The private sector cannot do everything. Without the State, would we have carried out the nuclear program or the TGV? Certainly not!

We have therefore decided to mobilize 35 billion euros of national borrowing that will be exclusively dedicated to future priorities.

Thus, more than 60 billion euros, public and private, will be invested in five priority areas: higher education and training, research, industry and SMEs, digital technology, and finally sustainable development.

In 2006, we invested proportionally half as much as the United States in higher education. Half as much!

In France, higher education spending as a percentage of GDP even decreased between 1995 and 2006.

Since 2007, as I committed to do, the State's effort has increased by one billion euros each year. In five years, if we add the campus plan, it will be an additional 20 billion euros for higher education.

And we have launched the Campus operation so that students finally have modern facilities, decent university housing, and accessible libraries.

We will also allocate 1 billion euros immediately to Saclay to create a gigantic campus for education, research, and valorization.

Our universities suffered from a lack of autonomy and, it must be said, archaic governance. We have put an end to this with the law on university autonomy.

With the national borrowing, we are taking a new step. We will give our universities the means to achieve excellence.

Our objective is simple: to create a dozen campuses of excellence with the means, critical size, and links with businesses that will allow them to compete with the best universities in the world.

Eight billion euros will be dedicated to this according to strict criteria defined by an international jury.

Thus, with the Campus plan and its 5 billion, the real estate aspect is being addressed. With the National Borrowing and its 8 billion, the entire immaterial aspect is being tackled.

We want to be able to compete with the best universities in the world. We know perfectly well, dear Valérie PECRESSE, that autonomy is a necessary but not sufficient condition. Autonomy is not an end in itself.

After a rigorous selection process and a probationary period, a small number of universities will be able to receive a capital endowment of around 1 billion euros each. For the first time, French universities will benefit from resources that are not subject to the whims of budgetary arbitrations.

These funds will allow them to purchase cutting-edge equipment, but above all to establish a capital that generates sustainable income. To enable them to recruit the best researchers and launch the best projects.

Our support is, however, subject to three conditions:

- global excellence,

- renewed governance, and

- partnership with businesses.

France allocates significant resources to public research. We take pride in having several Nobel laureates in scientific disciplines. But we suffer from the dispersion of forces and the compartmentalization between public research and the economic world. And we are very behind in patent filings and their valorization.

I have been told that our research organizations hold hundreds of dormant patents, perhaps more. So, there are two possibilities: either these patents are obsolete, and we need to stop paying for their maintenance, or they are potentially valuable and we need to bring them to industrial application. We will have these patents evaluated.

We will provide capital to a small number of valorization companies located on major campuses. I want to help those who valorize these patents and who try to give them an industrial translation.

The top priority, health research, which is dear to you, Ladies and Gentlemen.

2.5 billion euros out of the 8 billion will be allocated to health research and biotechnology. Cardiovascular diseases that concern you today, cancers, diabetes, obesity, genetic diseases, Alzheimer's, and AIDS: these are hundreds of thousands of families that are affected, broken.

The "Health and Biotechnology" action of the Grand Emprunt will support health research, so that an economy based on the knowledge of living beings and renewable biological resources emerges.

It has a total funding of 1.55 billion euros for the establishment of cohorts, high-throughput platforms, biotechnology infrastructures, and bioinformatics.

There is a project that is particularly close to my heart, which is that of the hospital-university institutes, the IHUs. Our idea is to bring together the excellence of care with the best of medical research around coherent scientific projects, so that from this alliance, diagnostic and therapeutic innovations emerge, sources of prosperity, growth, and jobs. We will dedicate nearly one billion euros to them.

A first call for proposals will take place in the coming months, and we will select the first five IHUs. Our goal is to identify within our universities, in our university hospitals, five projects of global excellence and to support them until their industrial translation. To concentrate very significant resources on a small number of teams to enable them to position themselves in global competition.

Since 2007, we have made a massive effort to achieve this. With the reform of the Research Tax Credit, we have become one of the most attractive countries. And the reform of the professional tax will result, starting next year, in a reduction of local taxes paid by industrial companies.

And I fully expect, Ladies and Gentlemen, that this public investment plan will attract significant additional investments from the industrial sector, from Europe, and from local authorities.

This is therefore an absolutely exceptional effort in favor of investment. This effort cannot be diverted to benefit the current expenses of the administration. The funds mobilized by the National Borrowing will be distinct from those of the State budget. They will be allocated to well-identified operators.

A General Commissioner for Investment is responsible for setting up this system.

The investments we have decided on are investments for the next 20 or 30 years.

We must turn to health, biotechnology, innovative treatments, sustainable growth, renewable energies, digital technology, and high-speed internet.

I am determined not to miss this opportunity for France to cooperate with the world's largest pharmaceutical laboratories.

I am determined to ensure that health industries become a major axis of France's competitiveness.

I know I can count on you. You know you can count on me.